Executive Committee

Dr Roch Doliveux

Chief Executive Officer and Chairman of the Executive Committee

Appointed in January 2005. Previously Director-General of UCB's Pharma Sector; CEO of Pierre Fabre Pharmaceuticals; President of Schering-Plough International, plus other posts with this company in the US, France and Belgium. Started at Ciba-Geigy (now Novartis), working in Switzerland, Peru and France. He is a member of the Board of Directors of UCB, and also a member of the Board of the European Federation of Pharmaceutical Industries & Associations (EFPIA). 

Detlef Thielgen

Executive Vice President and Chief Financial Officer

Appointed in January 2007. Previously CFO of Schwarz Pharma AG, Managing Director of Schwarz Pharma Operations covering the worldwide manufacturing and supply chain functions and Vice-President Finance & Administration/CFO at Schwarz Pharma Inc/USA.

Dr Melanie Lee

Executive Vice President, Research

Appointed in July 2004. Previously Executive R&D Director at Celltech and Research Unit Head at Glaxo Welcome (now GSK). Also chairs Cancer Research Technology, the technology transfer subsidiary of Cancer Research UK (CRUK) and is a CRUK Trustee. Elected fellow of the Academy of Medical Sciences (U.K. - 2003) and awarded honorary doctorate by University of York (U.K. - 2004).

Iris Löw-Friedrich

Executive Vice President, Development and Chief Medical Officer

Appointed in March 2008.  Previously Head of R&D and member of the Executive Board of Schwarz Pharma AG, after having held the position of VP Global Projects at BASF Pharma.  Since June 2007, she is also a member of the Supervisory Board of Wilex AG.

Fabrice Enderlin

Executive Vice President, corporate Human Ressources

Appointed in March 2008.  Previously  Vice President Human Resources at GSK Biologicals, and at GSK France, Novartis, and Arcelor/Mittal. Graduated from the “Political Sciences Institut” and has a master degree in HR.
 

Bill Robinson

Executive Vice President, Global Operations

Appointed in April 2005. Previously 30+ years with Eli Lilly as Vice President, Operational Excellence; Vice President, Sales & Marketing U.S.A. and a number of other marketing and general management roles in Europe, Africa, Asia-Pacific and U.S.A. He is also a member of the Board of Directors of Sciele Pharma, Inc.

Bob Trainor

Executive Vice President and General Counsel

Appointed in October 2004. Previously Vice President, Associate General Counsel of Schering-Plough; Assistant General Counsel of Johnson & Johnson; Attorney with the New York law firm Donovan Leisure Newton & Irvine and started as Counsel of the Committee on the Judiciary at the United States House of Representatives.

Mark McDade

Executive Vice President, Corporate Strategy and Business Development

Mark McDade joined UCB SA as Executive Vice President, Corporate Strategy and Business Development in April 2008.  From 2002 until late 2007 he was Chief Executive Officer and a Director of PDL BioPharma, Inc.  Prior to PDL, he served as CEO of Signature BioScience, Inc. and was previously a co-founder and director of Corixa Corporation, where he served as Chief Operating Officer from September 1994 through December 1998 and as President and Chief Operating Officer from January 1999 until his departure in late 2000. Before Corixa, Mark McDade was Chief Operating Officer of Boehringer Mannheim – Therapeutics, and prior to that held several positions at Sandoz Ltd. including business development, product management and general management. Mark McDade received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School.

Michele Antonelli

Executive Vice President Technical Operations & Quality Assurance

Appointed in September 2007. Michele has a degree in Plant Biology from the University of Bari, Italy, and qualified the ENI's post graduate program in Biotechnology and in Advanced Genetics (molecular and somatic cell) at the Catholic University of Piacenza and the Iowa State University of Ames, USA.
From 1985 to 1992, he worked at Enichem, in Italy, as Research Fellow and then Head of the Molecular and Cell Biology Unit.  In 1992 he joined Serono where he held several senior managerial positions until the present day, gathering about 15 years experience in the QA and Manufacturing fields.  His last position there was as Senior Vice President Biotech Manufacturing & Process Development, based in Geneva.